![]()
- GM CEO Starts Opel Charm Tour in Germany
- Look Ahead: 'Risk On' Attitude Could Fuel Rally Further
- European Commission Objects to Sun Micro-Oracle Deal
- Obama Sees Strains Unless US, China Balance Growth
- JPMorgan Lifts Salary Freeze Amid Recovery
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Do You Know Your Coca-Cola Myths?
- Buffett to Sell Stakes in Norfolk Southern, Union Pacific
- Cramer: 5 Stocks to Play the Next Bull Run
- Why Google is Paying $750 Million for Ad Mob
- Warren Buffett to Sell Stakes In Union Pacific & Norfolk Southern
- Nov. 9: Unusual Volume Leaders
- The Battered Businesses Behind Housing
- Modern Warfare 2's Record-Breaking Launch
- Merck’s Mega-Monday Morning
- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- S&P Stocks Trading at New 52-Week Highs
MOST SHARED
- Obama Sees Strains Unless US, China Balance Growth
- Future of Marketing
- Priceline Crushes Profit Forecasts; Shares Jump
- Mad Mail: Buy the Berkshire Hathaway Split?
- European Commission Objects to Sun Micro-Oracle Deal
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Oil Tomorrow
- Framed for Porn – By a PC Virus
- Nov. 9: Unusual Volume Leaders
The chief executive of Schering-Plough [SGP
Loading...
()
] told CNBC that the drug company's latest earnings are a further sign that a three-year-old restructuring is having a positive impact.
"We are going into this year with momentum, we are growing very nicely on the top line, we're exerting financial discipline, and our bottom line is growing faster than our top line," CEO Fred Hassan said in an appearance on "Power Lunch" on Monday. "That's a great strategy to have."
The company announced fourth-quarter earnings Monday morning in-line with Wall Street expectations.
"What's very, very good is to see that this company--that was in dire straits three-and-a half years ago--has had its first three years of a strategic plan come through beautifully," Hassan added. "We're a much stronger company than we were three-and-a half years ago."
The company, based in Kenilworth, N.J., reported an adjusted profit of 17 cents per share on sales of $2.7 billion, compared with the Thomson Financial consensus forecasts of 17 cents and $2.53 billion, respectively.
Schering-Plough, which co-markets cholesterol drug Vytorin with Merck [MRK
Loading...
()
], logged $1.1 billion in sales of cholesterol drugs in the quarter. Sales of arthritis drug Remicade rose 34% from the year-ago period to $337 million.
James Kelly of Goldman Sachs raised the price target on the stock to $28 from $25 but said the company will need to find new areas of growth as sales of cholesterol drugs Vytorin and Zetia cool off.
"Schering-Plough’s key strategic challenge is diversification of the revenue base, away from the cholesterol franchise," Kelly wrote in a research report sent to clients on Monday.
"The growth of Nasonex and Remicade are important avenues of diversification, and we will watch the impact of new competition on these franchises."
Merrill Lynch's David Risinger expressed a similar sentiment, saying investor attention will be closely focused on the slowdown in the cholesterol drug market.
"Cholesterol market new prescription growth has been cut in half recently, to approximately 6% to 7% year-over-year growth in the last three weeks versus 13% growth in full-year 2006," Risinger said.
- Do free market libertarians really believe what they say about ethics and shareholder value? The Big Money takes a look.
- Cramer did the research and found eight stocks that lead the pack. Read on to get his top picks.
- On the anniversary of the fall of the Berlin Wall, many in the former Eastern Bloc recall communism fondly.
- Software, biotech firms, even banks are watching a particular Supreme Court argument today.
- From politicians to CEOs to companies, here's your chance to vote for the winners and losers of 2009.
- A new sinister Internet viruses can turn you into an unsuspecting collector of child pornography.











